EDITORIAL: The Medication Affordability and Patent Integrity Act puts data at risk while raising costs. Republicans should vote no.

Hill sources tell us the Senate HELP Committee will soon vote on Sen. Maggie Hassan’s (D., N.H.) Medication Affordability and Patent Integrity Act. The bill would put private healthcare data at risk, expand the bureaucracy, and increase costs. Republicans should vote no.

The bill is marketed as a way to bring down drug prices. It will do nothing of the sort. By the sponsors’ own estimate, the Congressional Budget Office pegged the savings at roughly $100 million over a decade, a rounding error compared to trillions in healthcare spending. And the costs would far exceed the savings with a new layer of federal paperwork, a new front for patent litigation, and a fresh opening for the trial bar. Here is why Republicans should oppose this. 

First, the bill creates serious data security risks by requiring the transfer of vast amounts of confidential health data to the Patent and Trademark Office. A typical drug application submitted to the FDA can exceed 200,000 pages of highly sensitive scientific and commercial information. The FDA has extensive experience safeguarding this material. The Patent and Trademark Office, by contrast, is primarily focused on public disclosure and lacks the FDA’s expertise in handling sensitive biomedical data. As Sen. Chuck Grassley (R., Iowa), recently noted, China’s efforts to steal proprietary health care information and intellectual property continue to grow. This legislation would create new opportunities for foreign adversaries to gain access to valuable American research and development data.

Second, the law already polices this conduct. Courts already void patents secured through inequitable conduct, and the doctrine has been on the books for generations. Backers point to so-called patent thickets and gaming between agencies, but they have produced anecdotes, not evidence of a systemic failure the courts cannot already reach. Republicans should be wary of standing up a new federal regime on the premise that the existing one might be falling short.

Third, it manufactures bureaucracy and litigation. The bill would force drugmakers to thread new certification requirements between the FDA and the Patent Office, two agencies built for different jobs. Worse, it creates a new non-disclosure defense against infringement, turning patent suits into fights over regulatory paperwork instead of the merits of the invention. That is a standing invitation to the plaintiffs’ bar which is almost entirely Democratic. This would ultimately mean higher healthcare costs for patients. 

Fourth, just look at where the idea comes from. The intellectual and financial engine here runs through groups like Arnold Ventures and the constellation of left-wing groups that have spent years arguing for weaker IP, more federal control of innovation, and price controls. When the loudest applause comes from the people most hostile to private markets, that is a reason for conservatives to look harder, not to sign on.

Finally, this is the wrong tool. President Trump’s Trump Rx win showed that real savings are possible without dismantling the patent protections that underwrite American medical innovation. If lawmakers want lower costs, the target is the middlemen, the pharmacy benefit managers and insurers who set prices behind closed doors, not the inventors who take the risks.

Conservatives defend property rights because they drive the investment and risk-taking that produce new drugs in the first place. The Medication Affordability and Patent Integrity Act trades that away for paperwork, lawsuits, and uncertainty.

Republicans should vote no.